- Trial phase
- Approved
- Time to market
- Already approved and launching in the US as of October 2026.
- Why 4/10
- Juvmo was FDA-approved on September 28, 2026, and the next hard catalyst (first commercial sales data in Q4 2026 earnings) is not a binary regulatory event. As an approved drug at a mega-cap company, the impact score is capped at 4 per the rubric.
Juvmo was approved on September 28, 2026, and AbbVie guided to a US launch in October 2026. The next catalysts are Q4 2026 first sales disclosures, Medicare coverage decisions, and real-world adoption data. For a company the size of AbbVie, Juvmo is a pipeline validation story, not a binary event.
Price Chart
Executive Summary
Juvmo (tavapadon) is a first-in-class, once-daily oral selective D1/D5 dopamine receptor partial agonist approved by the FDA on September 28, 2026, for adults with Parkinson's disease. Developed by AbbVie (ABBV) through its $8.7 billion acquisition of Cerevel Therapeutics, Juvmo is the first approved drug in its mechanistic class. Phase 3 TEMPO trials demonstrated significant motor-symptom improvement both as monotherapy in early Parkinson's and as an add-on to levodopa. For AbbVie, a mega-cap pharma company, Juvmo is a pipeline-validation story and a long-term commercial asset, but it is too small relative to AbbVie's overall revenue to be a major stock-moving catalyst.
How It Works
Juvmo is a once-daily pill that mimics dopamine, a brain chemical that Parkinson's disease depletes. Unlike older dopamine agonists that activate D2 and D3 receptors, Juvmo selectively activates D1 and D5 receptors, a different subtype. This partial activation is designed to improve motor symptoms while potentially causing fewer side effects like impulse-control disorders.
Trial Status
FDA approval was based on the Phase 3 TEMPO program (TEMPO-1, TEMPO-2, TEMPO-3), which evaluated tavapadon as monotherapy in early Parkinson's and as adjunctive therapy with levodopa in patients with motor fluctuations. TEMPO-2 results were published in The Lancet Neurology. A long-term open-label extension (TEMPO-4) showed continued efficacy through 85 weeks.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 earnings (first sales disclosure for Juvmo)
- Medicare coverage and formulary decisions
- Real-world adoption and prescription data
- Potential ICER cost-effectiveness assessment
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report